Towards a “metabolic” subtype of major depressive disorder: Shared pathophysiological mechanisms may contribute to cognitive dysfunction

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 10, 2014, Pages 1693-1707

  Liu, Celina S ^a,b   Carvalho, Andre F ^c   McIntyre, Roger S ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Body mass index; Co morbidity; Cognition; Major depressive disorder; Metabolic disorders; Obesity

Indexed keywords

ADIPONECTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; INSULIN; LEPTIN; NEUROTROPHIC FACTOR; RESISTIN; TRYPTOPHAN; TRYPTOPHAN CATABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC STRESS; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INSULIN RESISTANCE; MAJOR DEPRESSION; METABOLIC DISORDER; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PROSPECTIVE STUDY; QUALITY CONTROL; SCORING SYSTEM; SIGNAL TRANSDUCTION; COGNITION DISORDERS; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; MEDLINE; METABOLIC DISEASES; STATISTICS AND NUMERICAL DATA;

COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; METABOLIC DISEASES; OBESITY; PUBMED;

EID: 84924189682     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666141130204031     Document Type: Article

References (233)

1. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2013; 1-12.
2. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004; 26(1): 13-7.
3. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry 2014; 75(1): 8-14.
4. Pandina GJ, Revicki DA, Kleinman L, Turkoz I, Wu JH, Kujawa MJ, Mahmoud R, Gharabawi GM. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician-and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. J Affect Disord 2009; 118(1-3): 139-46.
5. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A metaanalysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord 2012; 140(2): 113-24.
6. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A. A metaanalysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 2012; 125(4): 281-92.
7. Hasselbalch BJ, Knorr U, Hasselbalch SG, Gade A, Kessing LV. Cognitive Deficits in the Remitted State of Unipolar Depressive Disorder. Neuropsychology 2012; 26(5): 642-51.
8. Kan C, Silva N, Golden SH, Rajala U, Timonen M, Stahl D, Ismail K. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care 2013; 36(2): 480-9.
9. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67(3): 220-9.
10. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a metaanalysis. Diabetes Care 2001; 24(6): 1069-78.
11. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De HA, Probst M, Scheewe TW, De HM. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2013; 1-12.
12. Morikawa M, Okamoto N, Kiuchi K, et al. Association between depressive symptoms and metabolic syndrome in Japanese community-dwelling older people: a cross-sectional analysis from the baseline results of the Fujiwara-kyo prospective cohort study. Int J Geriatr Psychiatry 2013; 28(12): 1251-9.
13. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997; 54(10): 915-22.
14. Steffens DC, Krishnan KR. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psychiatry 1998; 43(10): 705-12.
15. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin MP, Bennett B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995; 37(3): 151-60.
16. Krishnan KR, McDonald WM. Arteriosclerotic depression. Med Hypotheses 1995; 44(2): 111-5.
17. Salloway S, Malloy P, Kohn R, Gillard E, Duffy J, Rogg J, Tung G, Richardson E, Thomas C, Westlake R. MRI and neuropsychological differences in early-and late-life-onset geriatric depression. Neurology 1996; 46(6): 1567-74.
18. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry 1997; 154(4): 497-501.
19. Figiel GS, Krishnan KR, Doraiswamy PM, Rao VP, Nemeroff CB, Boyko OB. Subcortical hyperintensities on brain magnetic resonance imaging: a comparison between late age onset and early onset elderly depressed subjects. Neurobiol Aging 1991; 12(3): 245-7.
20. Lesser IM, Boone KB, Mehringer CM, Wohl MA, Miller BL, Berman NG. Cognition and white matter hyperintensities in older depressed patients. Am J Psychiatry 1996; 153(10): 1280-7.
21. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M. Clinically defined vascular depression. Am J Psychiatry 1997; 154(4): 562-5.
22. Napoli N, Shah K, Waters DL, Sinacore DR, Qualls C, Villareal DT. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. Am J Clin Nutr 2014; 100(1): 189-19.
23. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 2014; 20(3): 278-91.
24. Fergenbaum JH, Bruce S, Lou W, Hanley AJ, Greenwood C, Young TK. Obesity and lowered cognitive performance in a Canadian First Nations population. Obesity 2009; 17(10): 1957-63.
25. Yan CM, Deng QN, Zhong WZ. Correlations among metabolic syndrome and mild cognitive impairment. Zhonghua Yi Xue Za Zhi 2011; 91(45): 3193-6.
26. Andre C, Dinel AL, Ferreira G, Laye S, Castanon N. Diet-induced obesity progressively alters cognition, anxiety-like behavior and lipopolysaccharide-induced depressive-like behavior: Focus on brain indoleamine 2, 3-dioxygenase activation. Brain Behav Immun 2014; 41: 10-21.
27. Bray GA. Obesity: the disease. J Med Chem 2006; 49(14): 4001-7.
28. Viscogliosi G, Andreozzi P, Chiriac IM, et al. Depressive symptoms in older people with metabolic syndrome: is there a relationship with inflammation? Int J Geriatr Psychiatry 2013; 28(3): 242-7.
29. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther 2012; 136(1): 82-93.
30. Sanz CM, Ruidavets JB, Bongard V, et al. Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care 2013; 36(6): 1512-21.
31. Millan MJ, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012; 11(2): 141-68.
32. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46(12): 1604-10.
33. Pannekoek JN, van der Werff SJ, van den Bulk BG, et al. Reduced anterior cingulate gray matter volume in treatment-naive clinically depressed adolescents. Neuroimage Clin 2014; 4: 336-42.
34. Ramasubbu R, Konduru N, Cortese F, et al. Reduced intrinsic connectivity of amygdala in adults with major depressive disorder. Front Psychiatry 2014; 5: 17.
35. Young KD, Zotev V, Phillips R, et al. Real-time FMRI neurofeedback training of amygdala activity in patients with major depressive disorder. PLoS One 2014; 9(2): e88785.
36. Macht M. How emotions affect eating: a five-way model. Appetite 2008; 50(1): 1-11.
37. Hryhorczuk C, Sharma S, Fulton SE. Metabolic disturbances connecting obesity and depression. Front Neurosci 2013; 7: 177.
38. Bazakis AM, Kunzler C. Altered mental status due to metabolic or endocrine disorders. Emerg Med Clin North Am 2005; 23(3): 901-8.
39. Liu CS, Carvalho AF, Mansur RB, McIntyre RS. Obesity and bipolar disorder: synergistic neurotoxic effects? Adv Ther 2013; 30(11): 987-1006.
40. Watari K, Letamendi A, Elderkin-Thompson V, et al. Cognitive function in adults with type 2 diabetes and major depression. Arch Clin Neuropsychol 2006; 21(8): 787-96.
41. Watari K, Elderkin-Thompson V, Ajilore O, et al. Neuroanatomical correlates of executive functioning in depressed adults with type 2 diabetes. J Clin Exp Neuropsychol 2008; 30(4): 389-97.
42. Goveas JS, Espeland MA, Hogan PE, et al. Depressive Symptoms and Longitudinal Changes in Cognition: Women's Health Initiative Study of Cognitive Aging. J Geriatr Psychiatry Neurol 2014; 27(2): 94-102.
43. Wang YY, Chang YH, Lee SY, et al. Symptomatological and cognitive correlates of vascular comorbidity in older-elderly (at least 75 years old) men with major depressive disorder. Kaohsiung J Med Sci 2012; 28(11): 607-12.
44. Jagielski AC, Brown A, Hosseini-Araghi M, Thomas GN, Taheri S. The association between adiposity, mental well-being, and quality of life in extreme obesity. PLoS One 2014; 9(3): e92859.
45. Arterburn D, Westbrook EO, Ludman EJ, et al. Relationship between Obesity, Depression, and Disability in Middle-Aged Women. Obes Res Clin Pract 2012; 6(3): e197-e206.
46. Martinho KO, Dantas EH, Longo GZ, et al. Comparison of functional autonomy with associated sociodemographic factors, lifestyle, chronic diseases (CD) and neuropsychiatric factors in elderly patients with or without the metabolic syndrome (MS). Arch Gerontol Geriatr 2013; 57(2): 151-5.
47. Li S, Yun M, Fernandez C, et al. Cigarette smoking exacerbates the adverse effects of age and metabolic syndrome on subclinical atherosclerosis: the bogalusa heart study. PLoS One 2014; 9(5): e96368.
48. Buettner R, Scholmerich J, Bollheimer LC. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity (Silver Spring) 2007; 15(4): 798-808.
49. Morgan VA, McGrath JJ, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med 2013; 1-14.
50. Pasco JA, Jacka FN, Williams LJ, et al. Leptin in depressed women: cross-sectional and longitudinal data from an epidemiologic study. J Affect Disord 2008; 107(1-3): 221-5.
51. Jamal M, Willem Van der Does AJ, Cuijpers P, Penninx BW. Association of smoking and nicotine dependence with severity and course of symptoms in patients with depressive or anxiety disorder. Drug Alcohol Depend 2012; 126(1-2): 138-46.
52. Nunes SO, Vargas HO, Brum J, et al. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res 2012; 14(5): 540-6.
53. Pace TW, Miller AH. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 2009; 1179: 86-105.
54. Capuron L, Dantzer R. Cytokines and depression: the need for a new paradigm. Brain Behav Immun 2003; 17 Suppl 1: S119-S124.
55. Capuron L, Ravaud A, Gualde N, et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology 2001; 26(8): 797-808.
56. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med 2011; 13(2): 93-116.
57. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996; 20(4): 291-302.
58. Herieka M, Erridge C. High-fat meal induced postprandial inflammation. Mol Nutr Food Res 2014; 58(1): 136-46.
59. Arango V, Underwood MD, Mann JJ. Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 2002; 136: 443-53.
60. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(1): 85-102.
61. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2, 3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 702-21.
62. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65(9): 732-41.
63. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58(5): 445-52.
64. Grigoleit JS, Kullmann JS, Wolf OT, et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One 2011; 6(12): e28330.
65. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292(18): 2237-42.
66. Vogelzangs N, Beekman AT, van Reedt Dortland AK, et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology 2014; 39(7): 1624-34.
67. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53C: 23-34.
68. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54(3): 438-63.
69. Calder PC. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot Essent Fatty Acids 2008; 79(3-5): 101-8.
70. Murakami K, Sasaki S, Takahashi Y, et al. Total n-3 polyunsaturated fatty acid intake is inversely associated with serum C-reactive protein in young Japanese women. Nutr Res 2008; 28(5): 309-14.
71. Gertsik L, Poland RE, Bresee C, Rapaport MH. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012; 32(1): 61-4.
72. Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry 2008; 42(3): 192-8.
73. Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun 2012; 26(6): 988-95.
74. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006; 91(2): 439-46.
75. Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc 2003; 51(8): 1125-30.
76. Lee IM, Sesso HD, Ridker PM, et al. Physical activity and inflammation in a multiethnic cohort of women. Med Sci Sports Exerc 2012; 44(6): 1088-96.
77. Gano LB, Donato AJ, Pierce GL, et al. Increased proinflammatory and oxidant gene expression in circulating mononuclear cells in older adults: amelioration by habitual exercise. Physiol Genomics 2011; 43(14): 895-902.
78. Ellis A, Crowe K, Lawrence J. Obesity-related inflammation: implications for older adults. J Nutr Gerontol Geriatr 2013; 32(4): 263-90.
79. Santos S, Oliveira A, Lopes C. Systematic review of saturated fatty acids on inflammation and circulating levels of adipokines. Nutr Res 2013; 33(9): 687-95.
80. Pasco JA, Williams LJ, Jacka FN, et al. Tobacco smoking as a risk factor for major depressive disorder: population-based study. Br J Psychiatry 2008; 193(4): 322-6.
81. Pedersen W, Von ST. Smoking, nicotine dependence and mental health among young adults: a 13-year population-based longitudinal study. Addiction 2009; 104(1): 129-37.
82. Patton GC, Carlin JB, Coffey C, et al. Depression, anxiety, and smoking initiation: a prospective study over 3 years. Am J Public Health 1998; 88(10): 1518-22.
83. Malone KM, Waternaux C, Haas GL, et al. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry 2003; 160(4): 773-9.
84. Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J Psychiatr Res 2003; 37(5): 357-73.
85. Nunes SO, Vargas HO, Prado E, et al. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev 2013; 37(8): 1336-45.
86. Fernstrom JD. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 1983; 63(2): 484-546.
87. Lapin IP. Neurokynurenines (NEKY) as common neurochemical links of stress and anxiety. Adv Exp Med Biol 2003; 527: 121-5.
88. Mackay GM, Forrest CM, Stoy N, et al. Tryptophan metabolism and oxidative stress in patients with chronic brain injury. Eur J Neurol 2006; 13(1): 30-42.
89. Maes M, Scharpe S, Meltzer HY, et al. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994; 54(2): 143-60.
90. DeMyer MK, Shea PA, Hendrie HC, Yoshimura NN. Plasma tryptophan and five other amino acids in depressed and normal subjects. Arch Gen Psychiatry 1981; 38(6): 642-6.
91. Joseph MS, Brewerton TD, Reus VI, Stebbins GT. Plasma Ltryptophan/neutral amino acid ratio and dexamethasone suppression in depression. Psychiatry Res 1984; 11(3): 185-92.
92. Curzon G. Study of disturbed tryptophan metabolism in depressive illness. Ann Biol Clin 1979; 37(1): 27-33.
93. Banki CM, Molnar G, Fekete I. Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression. Arch Psychiatr Nervenkr 1981; 229(4): 345-53.
94. Maes M, Kubera M, Leunis JC, Berk M. Increased IgA and IgM responses against gut commensals in chronic depression: further evidence for increased bacterial translocation or leaky gut. J Affect Disord 2012; 141(1): 55-62.
95. Anderson G, Maes M. Oxidative/Nitrosative Stress and Immunoinflammatory Pathways in Depression: Treatment Implications. Curr Pharm Des 2013; 46: 224-35.
96. Maes M, Rief W. Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 2012; 196(2-3): 243-9.
97. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharideinduced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14(5): 511-22.
98. Pertovaara M, Raitala A, Juonala M, et al. Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007; 148(1): 106-11.
99. Niinisalo P, Raitala A, Pertovaara M, et al. Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008; 68(8): 767-70.
100. Finkelstein JA, Chance WT, Fischer JE. Brain serotonergic activity and plasma amino acid levels in genetically obese Zucker rats. Pharmacol Biochem Behav 1982; 17(5): 939-44.
101. Brandacher G, Winkler C, Aigner F, et al. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes Surg 2006; 16(5): 541-8.
102. Chess AC, Simoni MK, Alling TE, Bucci DJ. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 2007; 33(3): 797-804.
103. Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res 2006; 170(2): 326-32.
104. Frodl T, O'Keane V. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis 2013; 52: 24-37.
105. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2(2): 73-86.
106. Axelson DA, Doraiswamy PM, McDonald WM, et al. Hypercortisolemia and hippocampal changes in depression. Psychiatry Res 1993; 47(2): 163-73.
107. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 17 Suppl 3: 306-10.
108. Duman RS. Depression: a case of neuronal life and death? Biol Psychiatry 2004; 56(3): 140-5.
109. Belanoff JK, Kalehzan M, Sund B, et al. Cortisol activity and cognitive changes in psychotic major depression. Am J Psychiatry 2001; 158(10): 1612-6.
110. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 2002; 7(3): 254-75.
111. Prestele S, Aldenhoff J, Reiff J. The HPA-axis as a possible link between depression, diabetes mellitus and cognitive dysfunction. Fortschr Neurol Psychiatr 2003; 71(1): 24-36.
112. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition 1997; 13(9): 795-803.
113. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 1974; 136: 1-186.
114. Hoes MJ, Sijben N. The clinical significance of disordered renal excretion of xanthurenic acid in depressive patients. Psychopharmacology 1981; 75(4): 346-9.
115. Young SN. Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol 1981; 74(3): 695-700.
116. Desbriere R, Vuaroqueaux V, Achard V, et al. 11betahydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity 2006; 14(5): 794-8.
117. Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav 2014; 38C: 148-59.
118. Juruena MF, Cleare AJ, Papadopoulos AS, et al. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology 2006; 189(2): 225-35.
119. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 722-9.
120. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr 2004; 26(3): 189-201.
121. Lee SY, Lee SJ, Han C, et al. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 224-35.
122. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006; 97(6): 1634-58.
123. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. The implication of obesity on total antioxidant capacity in apparently healthy men and women: the ATTICA study. Nutr Metab Cardiovasc Dis 2007; 17(8): 590-7.
124. Chai W, Conroy SM, Maskarinec G, et al. Associations between obesity and serum lipid-soluble micronutrients among premenopausal women. Nutr Res 2010; 30(4): 227-32.
125. Galan P, Viteri FE, Bertrais S, et al. Serum concentrations of betacarotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. Eur J Clin Nutr 2005; 59(10): 1181-90.
126. Freeman LR, Zhang L, Nair A, et al. Obesity increases cerebrocortical reactive oxygen species and impairs brain function. Free Radic Biol Med 2013; 56: 226-33.
127. Medina-Gomez G. Mitochondria and endocrine function of adipose tissue. Best Pract Res Clin Endocrinol Metab 2012; 26(6): 791-804.
128. Dash SK. Cognitive impairment and diabetes. Recent Pat Endocr Metab Immune Drug Discov 2013; 7(2): 155-65.
129. Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 2012; 68(4): 701-11.
130. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32(1): 7-24.
131. Galecki P, Talarowska M, Bobinska K, et al. Thiol protein groups correlate with cognitive impairment in patients with recurrent depressive disorder. Neuro Endocrinol Lett 2013; 34(8): 780-6.
132. Zhao B, Pan BS, Shen SW, et al. Diabetes-induced central neuritic dystrophy and cognitive deficits are associated with the formation of oligomeric reticulon-3 via oxidative stress. J Biol Chem 2013; 288(22): 15590-9.
133. Won SJ, Yoo BH, Kauppinen TM, et al. Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J Neuroinflammation 2012; 9: 182.
134. Cardoso S, Santos RX, Correia SC, et al. Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis 2012; 49C: 1-12.
135. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49(10): 1255-60.
136. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272(5656): 827-9.
137. Baskin DG, Porte D Jr, Guest K, Dorsa DM. Regional concentrations of insulin in the rat brain. Endocrinology 1983; 112(3): 898-903.
138. Unger JW, Moss AM, Livingston JN. Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat. Neuroscience 1991; 42(3): 853-61.
139. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep 2012; 4: 14.
140. Air EL, Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin combine additively to reduce food intake and body weight in rats. Endocrinology 2002; 143(6): 2449-52.
141. McGowan MK, Andrews KM, Fenner D, Grossman SP. Chronic intrahypothalamic insulin infusion in the rat: behavioral specificity. Physiol Behav 1993; 54(5): 1031-4.
142. van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia 2010; 53(1): 58-65.
143. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3(3): 169-78.
144. Novak V, Milberg W, Hao Y, et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care 2014; 37(3): 751-9.
145. Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008; 131(Pt 12): 3311-34.
146. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004; 490(1-3): 71-81.
147. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008; 70(6): 440-8.
148. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289(5487): 2122-5.
149. Konner AC, Hess S, Tovar S, et al. Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab 2011; 13(6): 720-8.
150. Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007; 317(5836): 369-72.
151. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol 1989; 40: 191-225.
152. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn Sci 2011; 15(1): 37-46.
153. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol 2013; 4: 71.
154. Thaler JP, Choi SJ, Schwartz MW, Wisse BE. Hypothalamic inflammation and energy homeostasis: resolving the paradox. Front Neuroendocrinol 2010; 31(1): 79-84.
155. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? Ann Clin Psychiatry 2007; 19(4): 257-64.
156. Merlio JP, Ernfors P, Kokaia Z, et al. Increased production of the TrkB protein tyrosine kinase receptor after brain insults. Neuron 1993; 10(2): 151-64.
157. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997; 17(7): 2295-313.
158. Acheson A, Conover JC, Fandl JP, et al. A BDNF autocrine loop in adult sensory neurons prevents cell death. Nature 1995; 374(6521): 450-3.
159. Huang EJ, Reichard LF. Neurotrophins: role in neuronal development and function. Annu Rev Neurosci 2001; 24: 677-736.
160. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19(6): 1290-300.
161. Kokaia M, Ernfors P, Kokaia Z, Elmer E, Jaenisch R, Lindvall O. Suppressed epileptogenesis in BDNF mutant mice. Exp Neurol 1995; 133(2): 215-24.
162. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997; 9(12): 2581-7.
163. Lohof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature 1993; 363(6427): 350-3.
164. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci 1998; 11(4): 234-45.
165. Benraiss A, Chmielnicki E, Lerner K, Roh D, Goldman SA. Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 2001; 21(17): 6718-31.
166. Pencea V, Bingaman KD, Wiegand SJ, Luskin MB. Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci 2001; 21(17): 6706-17.
167. Yamada K, Nabeshima T. Brain-derived neurotrophic factor/TrkB signaling in memory processes. J Pharmacol Sci 2003; 91(4): 267-70.
168. Lindholm JS, Castren E. Mice with altered BDNF signaling as models for mood disorders and antidepressant effects. Front Behav Neurosci 2014; 8: 143.
169. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013; 14(1): 7-23.
170. Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 7(1): 18-21.
171. Duman RS, Monteggia LM. A Neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry 2006; 59(12): 1116-27.
172. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21(5): 679-82.
173. Cotman CW, Berchtold NC. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002; 25(6): 295-301.
174. Karege F, Bondolfi G, Gervasoni N, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity. Biol Psychiatry 2005; 57(9): 1068-72.
175. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008; 10(1): 95-100.
176. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64(6): 527-32.
177. Castren E, Rantamaki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010; 70(5): 289-97.
178. Zhou JX, Li HC, Bai XJ, et al. Functional Val66Met polymorphism of Brain-derived neurotrophic factor in type 2 diabetes with depression in Han Chinese subjects. Behav Brain Funct 2013; 9: 34.
179. Unger TJ, Calderon GA, Bradley LC, Sena-Esteves M, Rios M. Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J Neurosci 2007; 27(52): 14265-74.
180. Sharma S, Fulton S. Diet-induced obesity promotes depressive-like behaviour that is associated with neural adaptations in brain reward circuitry. Int J Obes 2013; 37(3): 382-9.
181. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112(2): 257-69.
182. Rothman SM, Griffioen KJ, Wan R, Mattson MP. Brain-derived neurotrophic factor as a regulator of systemic and brain energy metabolism and cardiovascular health. Ann NY Acad Sci 2012; 1264: 49-63.
183. Elmquist JK, Maratos-Flier E, Saper CB, Flier JS. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998; 1(6): 445-50.
184. Rosicka M, Krsek M, Matoulek M, et al. Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels. Physiol Res 2003; 52(1): 61-6.
185. Munzberg H, Myers MG Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 2005; 8(5): 566-70.
186. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest 2000; 105(12): 1827-32.
187. Lu XY. The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007; 7(6): 648-52.
188. Lu XY, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 2006; 103(5): 1593-8.
189. Antonijevic IA, Murck H, Frieboes RM, et al. Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 1998; 32(6): 403-10.
190. Rubin RT, Rhodes ME, Czambel RK. Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Res 2002; 113(3): 255-68.
191. Jow GM, Yang TT, Chen CL. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 2006; 90(1): 21-7.
192. Deuschle M, Blum WF, Englaro P, et al. Plasma leptin in depressed patients and healthy controls. Horm Metab Res 1996; 28(12): 714-7.
193. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13(2): 84-9.
194. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1): 79-83.
195. Narita K, Murata T, Takahashi T, et al. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30(6): 1159-62.
196. Leo R, Di Lorenzo G, Tesauro M, et al. Decreased plasma adiponectin concentration in major depression. Neurosci Lett 2006; 407(3): 211-3.
197. Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Smoking, fat mass and activation of the tumor necrosis factor-alpha pathway. Int J Obes Relat Metab Disord 2003; 27(12): 1552-6.
198. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003; 14(6): 561-6.
199. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002; 290(3): 1084-9.
200. Okamoto M, Ohara-Imaizumi M, Kubota N, et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 2008; 51(5): 827-35.
201. Ukkola O. Resistin-a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002; 147(5): 571-4.
202. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111(2): 225-30.
203. Gomez-Ambrosi J, Fruhbeck G. Do resistin and resistin-like molecules also link obesity to inflammatory diseases? Ann Intern Med 2001; 135(4): 306-7.
204. Rea R, Donnelly R. Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity? Diabetes Obes Metab 2004; 6(3): 163-70.
205. Brunetti L, Orlando G, Recinella L, et al. Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol 2004; 493(1-3): 41-4.
206. Doherty GH. Obesity and the ageing brain: could leptin play a role in neurodegeneration? Curr Gerontol Geriatr Res 2011; 2011: 708154.
207. Taylor VH, Macqueen GM. The Role of Adipokines in Understanding the Associations between Obesity and Depression. J Obes 2010; 2010: pii: 748048.
208. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann NY Acad Sci 2010; 1212: E1-19.
209. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124(1 Suppl): S3-18.
210. Tahrani AA, Bailey CJ, Del PS, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378(9786): 182-97.
211. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89(18): 8641-5.
212. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379(6560): 69-72.
213. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9(9): 1173-9.
214. Navarro M, Rodriquez de FF, Alvarez E, et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 1996; 67(5): 1982-91.
215. Cabou C, Campistron G, Marsollier N, et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008; 57(10): 2577-87.
216. Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. Am J Med Sci 2012; 343(1): 21-6.
217. McIntyre RS, Powell AM, Kaidanovich-Beilin O, et al. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 2013; 237: 164-71.
218. Isacson R, Nielsen E, Dannaeus K, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol 2011; 650(1): 249-55.
219. Gault VA, Porter WD, Flatt PR, Holscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int J Obes 2010; 34(8): 1341-4.
220. Stranahan AM, Norman ED, Lee K, et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008; 18(11): 1085-8.
221. Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol 2005; 8(1): 59-63.
222. Lin CH, Chen CC, Wong J, McIntyre RS. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. J Affect Disord 2014; 161: 123-6.
223. Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 2013; 18(5): 595-606.
224. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry 2006; 11(10): 892-902.
225. Wildes JE, Marcus MD, Fagiolini A. Obesity in patients with bipolar disorder: a biopsychosocial-behavioral model. J Clin Psychiatry 2006; 67(6): 904-15.
226. Tiwari HK, Patki A, Lieberman J, et al. Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). Front Genet 2011; 2: 56.
227. Park HR, Park M, Choi J, et al. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. Neurosci Lett 2010; 482(3): 235-9.
228. Forbes LE, Fraser SN, Downs SM, et al. Changes in dietary and physical activity risk factors for type 2 diabetes in Alberta youth between 2005 and 2008. Can J Public Health 2013; 104(7): e490-5.
229. Bian S, Gao Y, Zhang M, et al. Dietary nutrient intake and metabolic syndrome risk in Chinese adults: a case-control study. Nutr J 2013; 12: 106.
230. van Reedt Dortland AK, Giltay EJ, van VT, Zitman FG, Penninx BW. Personality traits and childhood trauma as correlates of metabolic risk factors: the Netherlands Study of Depression and Anxiety (NESDA). Prog Neuropsychopharmacol Biol Psychiatry 2012; 36(1): 85-91.
231. Danese A, Tan M. Childhood maltreatment and obesity: systematic review and meta-analysis. Mol Psychiatry 2014; 19(5): 544-54.
232. McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 2014; 156: 1-7.
233. Kudlow PA, Cha DS, Lam RW, McIntyre RS. Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. Sleep Med 2013; 14(10): 943-9.